Quantum Leap Healthcare Collaborative
The I-SPY Trials
For Patients
ABOUT
I-SPY 2 Trial
Resources
Funding & Support
Agents & Results
I-SPY Agents
Manuscripts
Meeting Abstracts
Collaborate
Proposal Submissions
Partner With Us
News
Latest News
Feature Articles
I-SPY in the News
Media Center
People
Leadership
Clinical Sites
Contact Us
FOR PATIENTS
News
News & Announcements
Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Close
Close
Close
I-SPY Email List Sign-up
First Name:
Last Name:
Email Address:
Breast cancer patient/family/friend
Research/Medical Professional
Just Interested
Thank you, your subscription is activated.
If you change your mind, you can
unsubscribe
at any time.
Oops! Something went wrong while submitting the form.
Older News
< BACK
September 14, 2018
-
News Update
Upcoming FDA workshop: "Clinical Trials to Optimize Outcomes in Early Breast Cancer"
September 12, 2018
-
Press Release
I-SPY 2, an Innovative Clinical Trial Model that is Revolutionizing the Treatment of Early Stage, High-Risk Breast Cancer
September 7, 2018
-
News Update
Advanced MRI methods tested in I-SPY 2 may improve monitoring and prediction of treatment response
September 6, 2018
-
Press Release
Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab For The I-SPY 2 Trial For Breast Cancer
May 30, 2018
-
News Update
I-SPY 2 TRIAL featuring three abstracts at ASCO's 2018 Annual Meeting
May 26, 2018
-
News Update
I-SPY founder Dr. Laura Esserman Honored: OncLive® To Induct the 2018 Class of Giants of Cancer Care®
December 7, 2017
-
Press Release
Long-term efficacy results from the I-SPY 2 TRIAL indicate pathological complete response (pCR) is a powerful predictor for breast cancer survival
December 7, 2017
-
Press Release
I-SPY 2 TRIAL predictive biomarker analysis shows promise to improve targeted therapy for high-risk breast cancers
August 21, 2017
-
Press Release
Natera's Personalized CtDNA Technology Now Part Of I-SPY 2 TRIAL
June 5, 2017
-
Press Release
New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck’s KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer
March 3, 2017
-
News Update
Healio Mentions I-SPY 2 Trial In "Five Updates For Triple Negative Breast Cancer Day"
February 24, 2017
-
News Update
Oncology Nursing News Mentions I-SPY Trials In New Agents, Combinations Showing Durable Benefit In Triple-Negative Breast Cancer
October 25, 2016
-
Press Release
Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer
July 7, 2016
-
Press Release
New England Journal of Medicine Underscores Success of the I-SPY 2 Clinical Trial Model as Promising Results are Published for Two Breast Cancer Drugs Investigated in the Study
April 18, 2016
-
Press Release
T-DM1 (Kadcyla) and pertuzumab (Perjeta) Show Promise for Women with HER2-positive Breast Cancer
March 21, 2016
-
Press Release
Keytruda, talazoparib join I-SPY 2
June 1, 2015
-
Press Release
Merck & Co. MK-2206 "Graduates" From I-SPY 2
December 11, 2014
-
Press Release
Plexxikon and QuantumLeap Healthcare Collaborative Announce Selection of PLX3397 for I-SPY 2 TRIAL in Breast Cancer
April 7, 2014
-
Press Release
I-SPY 2 Trial Identifies Subset of Breast Cancer Patients Most Likely to Benefit From Neratinib
March 11, 2014
-
Press Release
Synta and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer
December 26, 2013
-
Press Release
Foundation for the NIH Announces First Results of I-SPY 2 Breast Cancer Clinical Trial
March 17, 2010
-
Press Release
The Biomarkers Consortium launches I-SPY 2 breast cancer clinical trial
Don't miss a thing! Get I-SPY results, news and event information delivered right to your inbox.
Sign Up
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.